Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2014

View Archived Issues

Discovery and characterization of a novel class of Gram-positive antibacterial compounds

U.S. researchers patent new lentiviral vectors for stem cell gene therapy

Idenix Pharmaceuticals reports data for nucleotide prodrug development program

Bristol-Myers Squibb discloses novel fibronectin domain-based fusion proteins

Novel anti-IAPP MAbs divulged by Neurimmune Holding

UCB and Weill Cornell Medical College establish strategic research alliance

Ventana Medical Systems signs companion diagnostic agreement with Genmab

Novartis presents results from phase III studies of secukinumab

Pfizer gains access to IntegraGen's molecular signature for hepatocellular carcinoma

ValiRx establishes joint venture with Tangent Reprofiling

NLRP3 inflammasome inhibitor efficacious in model of ischemia-reperfusion injury

TetraLogic Pharmaceuticals to acquire Shape Pharmaceuticals

Two vemurafenib prodrugs developed with improved bioavailability

Ledipasvir/sofosbuvir combination gets FDA priority review

AbbVie designs new 5-HT2C receptor agonists

Novel tricyclic antibacterials presented by the LLNL and Cubist Pharmaceuticals

AEM-28 enters phase I/II trial in refractory hypercholesterolemia

TRV-130 begins phase II for acute postoperative pain after bunionectomy

Phase I trial to examine teprotumumab for new indication of diabetic macular edema

Phase I data on LY-2874455 shows safety and a favorable pharmacokinetic profile

Ambit Biosciences begins phase III QUANTUM-R trial

Kadmon Corporation initiates phase II study of KD-025 for psoriasis

Oncolytics Biotech reports additional data from Reolysin trial in head and neck cancer

RaQualia expands joint research agreement with Asahi Kasei Pharma

Thomson Reuters and Children's Tumor Foundation collaborate on neurofibromatosis pathway maps

Genentech presents new MEK inhibitors for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...